Commit To Purchase Stemline Therapeutics At $2.50, Earn 16.1% Annualized Using Options
February 02, 2016 at 11:45 AM EST
Investors considering a purchase of Stemline Therapeutics Inc (STML) stock, but cautious about paying the going market price of $4.72/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $2.50 strike, which has a bid at the time of this writing of 25 cents..